Antiemetic Study Methodology: Recommendations for Future Studies

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 96-101

  Olver, Ian N ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

5 HT3 receptor antagonists; Antiemetic; Cost effectiveness; Delayed emesis; Methodology

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DEXAMETHASONE; METOCLOPRAMIDE; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; CONFERENCE PAPER; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDICAL ETHICS; PRIORITY JOURNAL; VOMITING;

ANIMALS; ANTIEMETICS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; FORECASTING; HUMANS; SEROTONIN ANTAGONISTS;

EID: 0029812610     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227648     Document Type: Article

References (32)

1. Roila F, Tonato M, Cognctti F, Cortcsi E, Fa-valli G, Marangollo M, Amadori D, Bella MA, Gramazio V, Donati D, Ballatori E, Del Favero A: Prevention of cisplatin-induced emesis: A double-blind multicenter randomised crossover study comparing ondansetron and ondansetron plus dexamethasone, J Clin Oncol 1991: 9:675-678.
2. Dc Mulder PHM, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jcvdcvic S, Lanc-All-man E, Beranek P, Verweij J: Ondansetron compared to high-dosc metociopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting, Ann Intern Med 1990: 113:834-840.
3. Pollcra CF, Giamelli D: Prognostic factors influencing cisplatin-induced cmesis, Definition and validation of a predictive logistic model, Cancer 1989:64:1117-1122.
4. Olvcr IN, Simon RM, Aisncr J: Antiemetic studies: A methodological discussion, Canccr Treat Rep 1986:70:555-563.
5. Tonato M, Roila F, Del Favero A: Methodology of antiemetic trials: A review, Ann Oncol 1991:2:107-114.
6. Aapro M: Methodological issues in antiemetic studies, Invest New Drugs 1993; 11:243-253.
7. Higgins GA, Kilpatrick GJ, Buncc KT, Jones BJ, Tyers MB: 5-HTj receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret, J Pharmacol 1989: 97:247-255.
8. Milne RJ, Heel RC: Ondansetron, Therapeutic use as an antiemetic, Drugs 1991;41:574-595.
9. Grunbcrg SM, Hcsketh PJ: Control of chcmo-thcrapy-induced emesis, N Engl J Med 1993; 329:1790-1796.
10. Simon R: Design and conduct of clinical trials: in Dc Vita VT Jr, Heilman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology, Philadelphia, Lippincott, 1993, pp 420-421.
11. Hcsketh PJ, Harvey WH, Harkcr WG, Beck TM, Ryan T, Bricker LJ, Kish JA, Murphy WK, Hainsworth JD, Haley B, Plaggc P, Flack NE: A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dcxamcthasone in the prevention of high-dose cisplatin-induced emesis, J Clin Oncol 1994:12:596-600.
12. Bregni M, Siena S, Di Nicola M, Bonnadonna G, Gianni AM: Tropisctron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy, Eur J Cancer 1991:27:561-565.
13. Heristedt J, Sigsgaard T, Bocsgaard M, Jensen TP, Dombernowsky P: Ondansetron plus me-topima/.ine compared with ondansetron alone in patients receiving moderately cmetogenic chcmothcrapv, N Engl J Med 1993:328:1076-1080.
14. Tormey DC, Gelman R, Band PR, Scars M, Rosenthal SN, Dewys W, Perlia C, Rice MA: Comparison of induction chemotherapies for metastatic breast cancer, An Eastern Cooperative Oncology Group Trial, Cancer 1982:50: 1235-1244.
15. Aamdal S: Can ondansetron hydrochloride (Zofran) enhance the nephrotoxic potential of other drugs? (Letter), Ann Oncol 1992:3:774.
16. Jantunen IT, Muhonen TT, Kataja VV, Flan-der MK, Teercnhovi L: 5-HTj receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - A randomised study, Eur J Cancer 1993: 29A 1669-1672.
17. O'Brien BJ, Rusthovcn J, Rocchi A, Latreille J, Vandenberg T, Laberge F: Impact of chemo-therapy-associated nausea and vomiting on patients' functional status and on costs: Survey of five Canadian centres, Can Med Assoc J 1993: 149:296-302.
18. Plosker GL, Milne R.I: Ondansetron, A phar-macoeconomic and quality-of-life evaluation of its anticmctic activity in patients receiving cancer chemotherapy, Pharmacoeconomics 1992;2:285-304.
19. Beck TM: Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: Review of clinical trials, Semin Oncol 1992; 19(suppl 15):20-25.
20. Kris MG, Gralla RJ, Clark RA, Tyson I.B, O'Connell JP, Wertheim MS, Kelscn DP: Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin, J Clin Oncol 1985:3:1379-1384.
21. Roila F, Bracarda S, Tonato M, Marangolo M, Bella M, Donati D, Cetto G, Del Favero A: Ondansetron in the prophylaxis of acute and delayed cisplatin-induced emesis, Clin Oncol 1990;2:268-272.
22. Kris MG, Gralla RJ, Tyson LB, Clark RA, Cir-rincione C, Groshen S: Controlling delayed vomiting: Double-blind randomised trial comparing placcbo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin, J Clin Oncol 1989:7:208-214.
23. Kris MG, Tyson LB, Gralla RJ, Clark RA, Allen JC, Reilly LK: Extrapyramidal reactions with high-dose mctoclopramide (letter), N Engl J Med 1983;309:433-434.
24. Arcchevala E, Aulitzky W, Bocckmann W, Butcher ME, Deamaley DP, Droz J-P, Fossa S, Hcnricksson R, Jones W, Rath U, Upadhyaya BK, Weissbach L: A randomised double-blind comparative study of ondansetron plus dexa-mcthasone with metoclopramide plus dexamethasone as anticmetic prophylaxis during multi-day cisplatin chemotherapy (abstract), Proc Am Soc Clin Oncol 1992; 11:393.
25. Blijham GH, on behalf of the Granisetron Study Group: Does granisetron remain effective over multiple cycles? Eur J Cancer 1992; 28A(suppl 1):S 17-S21.
26. Cassidy J, Raina V, Lewis C, Aqdams L, Sou-koup M, Rapeport WG, Zussman BD, Rankin EM, Kaye SB: Pharmacokinetics and anticmetic efficacy of BRL43694, a new selective 5-HT antagonist, Br J Canccr 1988:58:651-653.
27. Jaoobsen SJ, Shore RW, Nishimura L, Mee D, Chan H, Spielberg SP: Efficacy and safety of granisetron in pediatric cancer patients who had failed standard anticmetic therapy during anticanccr chemotherapy (abstract), Eur J Cancer 1991:27(suppl 2):257.
28. Olver IN: Antiemctic study design: Desirable objectives, stratifications and analyses, Br J Cancer 1992:66(suppl XIX):S30-S34.
29. Cassileth BR, Lusk EJ, Bodenheimer BJ, Far-bcr JM, Jochimscn P, Morrin-Taylor B: Chemotherapeutic toxicity - The relationship between patients' pretreatment expectations and posttrcatment results, Am J Clin Oncol 1985;8: 419-425.
30. Beauchamp TL, Childress JF: Principles of Biomedical Ethics, New York, Oxford University Press, 1989, pp 349-353.
31. Olver IN, Matthews JP, Bishop JF, Smith RA: Th: roles of patient and observer assessments in antiemetic trials, Eur J Cancer 1994:30A: 1223-1227.
32. Fetting JH, Grochow LB, Folstcin MF, Ettin-ger DS, Colvin M: The course of nausea and vomiting after high-dose cyclophosphamide, CancerTreat Rep 1982;66:1487-1493.